White label ELPA - ClinicalTrials.eu

Study of Epcoritamab for Patients with Relapsed, Progressive, or Refractory B-Cell Lymphoma

Not recruiting

2 1 1 1
Investigated diseases:
- B-cell lymphoma refractory
Investigated drugs:
+3
Study Comparing Polatuzumab Vedotin with Rituximab, Ifosfamide, Carboplatin, and Etoposide for Adults with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Not recruiting

3 1 1 1
Investigated diseases:
Investigated drugs:
Study on Bepranemab for Patients with Early Alzheimer’s Disease

Not recruiting

2 1 1
Investigated diseases:
- Dementia Alzheimer’s type
Investigated drugs:
+1
Long-term Study on the Safety and Effectiveness of Odevixibat for Patients with Alagille Syndrome

Not recruiting

3 1 1 1
Investigated diseases:
- Alagille syndrome
Investigated drugs:
- Odevixibat
Study Comparing Epcoritamab with Chemotherapy for Patients with Relapsed or Refractory B-cell Lymphoma

Not recruiting

3 1 1 1
Investigated drugs:
+7
Study of Nivolumab and Relatlimab for Patients with Stage III-IV Melanoma After Surgery

Not recruiting

3 1 1 1
Investigated diseases:
- Malignant melanoma stage III
- Malignant melanoma stage IV
Investigated drugs:
- Nivolumab
- Relatlimab
+7
Study on the Effects of Nicotine Resinate Lozenge on Cravings in Moderate Smokers in Non-Smoking Situations

Not recruiting

3 1 1
Investigated drugs:
- Nicotine Resinate
Study on How Concizumab Works for Patients with Hemophilia A or B Without Inhibitors

Not recruiting

3 1 1
Investigated diseases:
- Factor IX deficiency
- Factor VIII deficiency
Investigated drugs:
- Concizumab
+5
Study on the Effectiveness and Safety of AZD4604 for Adults with Moderate-to-Severe Asthma Uncontrolled on Medium-High Dose ICS-LABA

Not recruiting

2 1
Investigated diseases:
- Asthma
Investigated drugs:
- (2R)-N-[3-(5-Fluoro-2-{[2-Fluoro-3-(Methylsulfonyl)Phenyl]Amino}-4-Pyrimidinyl)-1H-Indol-7-Yl]-3-Methoxy-2-(4-Methyl-1-Piperazinyl)Propanamide-1-Hydroxy-2-Naphthoic Acid
+1
Study on the Safety and Effectiveness of Ocrelizumab vs. Fingolimod for Children and Adolescents with Relapsing-Remitting Multiple Sclerosis

Not recruiting

3 1 1
Investigated diseases:
- Relapsing-remitting multiple sclerosis
Investigated drugs:
+11

Full Name *

e-Mail *

Country Prefix *

Phone Number *

Nationality *

Gender *

Check all consents

Check all consents

I accept the Terms and Conditions and Privacy Policy *

*I accept the Terms and Conditions and Privacy Policy

I consent to receiving commercial information from the Service Operator *

*I consent to receiving commercial information from the Service Operator

I consent to the use of telecommunications terminal equipment and automated calling systems by the Service Operator for marketing communication purposes *

*I consent to the use of telecommunications terminal equipment and automated calling systems by the Service Operator for marketing communication purposes

We use cookies